Impact Therapeutics Entered into Global Partnership with Eikon Therapeutics to Develop and Commercialize PARP1 Selective Inhibitors June 6, 2023
Lurbinectedin “Named Patient Program” for Small-Cell Lung Cancer launched in Hong Kong January 17, 2023
Merck Advances Development Programs in Oncology Focusing on Novel Mechanisms and Pathways June 13, 2022
